FICHIT

Je m'inscris

ONXEO

0/5 (0 note(s))
Note donnée : aucune
Paris
113
Onxeo is a leading developer of orphan oncology drugs. Onxeo’s vision is to become a global leader and pioneer in oncology, with a focus on orphan or rare cancers, by developing advanced, effective and safe therapeutics designed to improve the lives of patients.
Onxeo’s leading orphan oncology products at the advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Beleodaq® (belinostat): Registered in the US in 2nd-line treatment of peripheral T-cell lymphoma
Validive® (Clonidine Lauriad®): Phase II in severe oral mucositis: Positive final results
www.onxeo.com
ONXEO:FP

Fiche créée le 10/04/2016 par Guillaume   vue 5 fois.